All In Biotech

Drug Trial Radar · NCT06337032

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 27, 2024

Primary completion

Jun 2027

Study completion Mar 2034

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events. The primary objectives of this study are as follows: * To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment. * To evaluate the safety of the study drug(s) in participants with HIV-1.

Conditions

  • HIV-1-infection

Interventions

  • F/TAF (High Dose Tablet)Drug

    200/25 mg fixed-dose combination (FDC) tablet administered orally

  • F/TAF (Low Dose Tablet)Drug

    200/10 mg FDC tablet administered orally

  • F/TAF (Lowest Dose Tablet)Drug

    120/15 mg FDC tablet administered orally

  • F/TAF (High Dose TOS)Drug

    60/7.5 mg tablet for oral suspension (TOS) administered orally

  • F/TAF (Low Dose TOS)Drug

    30/3.75 mg TOS administered orally

  • F/TAF (Lowest Dose TOS)Drug

    15/1.88 mg TOS administered orally

  • E/C/F/TAFDrug

    150/150/200/10 mg tablet administered orally

  • E/C/F/TAF (Low Dose)Drug

    90/90/120/6 mg tablet administered orally

  • Cobicistat (High Dose)Drug

    150 mg tablet administered orally

  • Cobicistat (Low Dose)Drug

    90 mg tablet administered orally

  • Cobicistat (TOS)Drug

    30 mg TOS administered orally

  • B/F/TAF (High Dose)Drug

    50/200/25 mg FDC tablet administered orally

  • B/F/TAF (Low Dose)Drug

    30/120/15 mg FDC tablet administered orally

  • B/F/TAF (High Dose TOS)Drug

    15/60/7.52 mg TOS administered orally

  • B/F/TAF (Low Dose TOS)Drug

    7.5/30/3.76 mg TOS administered orally

  • B/F/TAF (Lowest Dose TOS)Drug

    3.76/15/1.88 mg TOS administered orally

  • 3rd ARV AgentDrug

    A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country

  • Nucleos(t)ide reverse transcriptase inhibitors (NRTI)Drug

    NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)

  • ATVDrug

    Administered according to the prescribing information

  • DRVDrug

    Administered according to the prescribing information

  • Lopinavir Boosted with ritonavir (LPV/r)Drug

    Administered according to the prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the StudyTime frame: Up to 2.8 Years

Locations

17 sites in 6 countries. Site status is shown where the registry gives one.

  • Helios Salud

    Buenos Aires, Argentina · Completed

  • Hospital del Niño

    Panama City, Panama · Completed

  • University of Stellenbosch

    Cape Town, South Africa · Recruiting

  • Enhancing Care Foundation

    Durban, South Africa · Recruiting

  • WITS RHI Research Centre

    Johannesburg, South Africa · Recruiting

  • Rahima Moosa Mother and Child Hospital

    Johannesburg, South Africa · Recruiting

  • Be Part Yoluntu Centre

    Paarl, South Africa · Recruiting

  • The Aurun Institute

    Pretoria, South Africa · Recruiting

  • Perinatal HIV Research Unit

    Soweto, South Africa · Recruiting

  • Faculty of Medicine - Mahidol University

    Bangkok Noi, Thailand · Active not recruiting

  • Khon Kaen University

    Khon Kaen, Thailand · Active not recruiting

  • Joint Clinical Research Centre

    Kampala, Uganda · Recruiting

  • MU-JHU Research Collaboration/MU-JHU Care Ltd

    Kampala, Uganda · Recruiting

  • Baylor College of Medicine

    Kampala, Uganda · Recruiting

  • Strengthening Institutional Capacity for Research Administration (SICRA)

    Kampala, Uganda · Recruiting

  • Africa Medical and Behavioral Sciences Organisation

    Masaka, Uganda · Recruiting

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.